[Etryptamine, a new designer drug with a fatal effect].
Capsules with etryptamine have been commonly available on the market since the middle of 1985. Up to 1962 this CNS-stimulating, monoamine-oxidase-inhibiting drug was sold as an antidepressant (Monase). A case of fatal intoxication is reported. The exact amount of etryptamine taken several hours before death are not known, but it could have been in the range of 700 mg. This drug was detected in tissue by means of common analytical techniques (GLC, GC-MS, HPLC, TLC). Etryptamine cross-reacts with the Emit-st amphetamine assay and can also be detected in urine using these techniques. The level in postmortem blood was 1.1 mg/l. The effects the young man showed were like those known from intoxication with amphetamines, MAO inhibitors, and thymoleptics. Malignant hyperthermia is discussed as a possible cause of death. It is suggested that trade in etryptamine should be controlled.
D000328:Adult; D004305:Dose-Response Relationship, Drug; D006801:Humans; D008297:Male; D012131:Respiratory Insufficiency / Q000139:chemically induced*; D014363:Tryptamines / Q000506:poisoning* / Q000652:urine
D014363:Tryptamines; C038034:etryptamine
Etryptamin, eine neue Designer-Droge mit fataler Wirkung.